Roivant Sciences Ltd. vs Johnson & Johnson
ROIV vs JNJ — side-by-side comparison from reported financials. ROIV leads 3, JNJ leads 6 of 9 comparable metrics.
Roivant Sciences Ltd.
ROIV · Healthcare
$35.44+3.60%Strong
Johnson & Johnson
JNJ · Healthcare
$261.79+2.07%Mixed
| Metric | ROIV | JNJ |
|---|---|---|
| Price | $35.44 | $261.79 |
| Market cap | $25.6B | $631B |
| Revenue (TTM) | $16.9M | $97.9B |
| Revenue growth | -48.7% | +5.6% |
| Net margin | -7594.2% | 21.5% |
| Free cash flow | -$1.89B | $22.2B |
| Net cash (debt) | $3.73B | ($27.8B) |
| 1-year price return | +119.9% | +37.0% |
| P/E | — | 29.9 |
| P/E vs own history (cheap-side %) | 73% | 16% |
| Dividend yield | — | 2.00% |
| Return on equity | -6% | 26% |
| Altman Z-score | 40.50 | — |
| CV checks passed | 5 of 9 | 10 of 9 |
| Employees | 721 | 140,800 |
Full résumé-style profiles: ROIV CV · JNJ CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.